in8bio.com (INAB) - Company Sales Volume

IN8bio (INAB) - corporate logo

IN8bio, Inc. (INAB) fully delegates medical testing to external contractors, minimizing operational disruptions. The company's gross sales level on the GURU.Markets daily price chart reflects current dynamics, where the indicator is fixed at 0.00. The business relies on venture capital, ignoring macroeconomic cycles, while the absence of a stable cash flow makes financial results dependent on clinical development milestones.

in8bio.com (INAB) Company Revenue: for the period 07/04/2022 - 11/15/2026

Analytical breakdowns for IN8bio, Inc.

- market price and analyst price targets:
Market Price IN8bio, Inc.|INAB - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization IN8bio Inc.|INAB - Enterprise Value
- issuer book value statistics:
Net Assets per Share IN8bio|INAB - Company Book Value|Capitalization to Book Value Ratio in8bio.com|INAB - Aggregate Asset Value
- debt and solvency information:
Total Debt to Capital IN8bio, Inc.|INAB - Long-Term Debt to Equity|Short-Term Debt to Capital IN8bio, Inc.|INAB - Company Total Debt Obligations|Debt to Book Capitalization Ratio IN8bio, Inc.|INAB - Long-Term Debt|Company Current Liabilities IN8bio|Quick Ratio in8bio.com
- earnings and market multiples details:
INAB - Net Financial Result|Expected Profit IN8bio, Inc.|INAB - Price to Earnings Multiple|Forward P/E Multiple IN8bio, Inc|INAB - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio IN8bio|INAB - Operating income before deduction of amortization|Net earnings per share (EPS TTM) IN8bio|INAB - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months in8bio.com|INAB - Earnings per share growth this year|Earnings growth forecast for next year IN8bio, Inc.
- sales volume and revenue indicators:
INAB - Revenue and Sales Volume|Projected Sales Volume in8bio.com|INAB - Price-to-Revenue Ratio|Forward P/S Multiple IN8bio Inc|INAB - Revenue Growth YoY (Last 12 Months)
Fundamental valuation:IN8bio, Inc
Core merchandise of IN8bio

A comparative asset analysis requires an assessment of daily inflows, which measure the resilience of market demand and signal risks of failing to meet corporate plans. The gross sales volume dynamics reflect the financial stability of IN8bio, Inc. (INAB), where reliance on grants and the success of blood cancer therapy determine the fundamental value of the business, as this chart clearly demonstrates.

Who IN8bio, Inc. competes with

Company Total Revenue TG Therapeutics, Inc. TGTX|Revenue and Sales Volume ACLX|Disc Medicine - Company Sales Volume|Company Revenue Syndax Corp SNDX|Revenue and Sales Volume Kura Oncology, Inc. KURA|ADC Therapeutics SA - Revenue and Sales Volume|Company Total Revenue foghorntx.com|VOR (Vor Biopharma) - Company Sales|Nkarta Corp (NKTX) - Revenue and Sales Volume|Company Revenue Coeptis|Actinium Corp (ATNM) - Company Gross Revenue|Revenue and Sales Volume ESLA|CASI (CASI Pharmaceuticals Inc.) - Company Sales Revenue|Company Revenue Marker Therapeutics MRKR|Revenue and Sales Volume eternatx.com ERNA|GTBP - Company Revenue|Company Sales Revenue APTO (aptose.com)|BPTH: Revenue and Sales Volume|meipharma.com - Company Sales Revenue|Company Revenue Vincerx